Investment Analysts’ Recent Ratings Changes for Generate Biomedicines (GENB)

Generate Biomedicines (NASDAQ: GENB) has recently received a number of price target changes and ratings updates:

• 4/13/2026 – Generate Biomedicines is now covered by HC Wainwright. They set a “buy” rating and a $16.00 price target on the stock.
• 3/25/2026 – Generate Biomedicines was upgraded by Zacks Research to “hold”.
• 3/24/2026 – Generate Biomedicines is now covered by Piper Sandler. They set an “overweight” rating and a $24.00 price target on the stock.
• 3/24/2026 – Generate Biomedicines is now covered by Morgan Stanley. They set an “overweight” rating and a $20.00 price target on the stock.
• 3/24/2026 – Generate Biomedicines is now covered by The Goldman Sachs Group, Inc.. They set a “buy” rating and a $26.00 price target on the stock.
• 3/24/2026 – Generate Biomedicines is now covered by Guggenheim. They set a “buy” rating and a $30.00 price target on the stock.
• 3/24/2026 – Generate Biomedicines is now covered by Cantor Fitzgerald. They set an “overweight” rating on the stock.
• 3/14/2026 – Generate Biomedicines was upgraded by Wall Street Zen to “hold”.

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.